ViiV Healthcare HIV drug Tivicay wins European OK
This article was originally published in Scrip
Executive Summary
Adults and adolescents with HIV in Europe were greeted with good news on 21 January after ViiV Healthcare said it won approval to market its new integrase inhibitor Tivicay (dolutegravir) in combination with other antiretrovirals as a treatment for the disease in patients 12 years or older.